Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Cash from Investing Activities came in at -$1.1 billion in Q2 2026, up 93.92% year-over-year from -$572.4 million in Q2 2025, and down 6.73% quarter-over-quarter from -$1.0 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$1.1 billion for Q2 2026.

  • In Q2 2026, Cash from Investing Activities rose 93.92% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at -$7.2 billion (up 68.81% YoY), while the FY2025 annual figure was -$23.6 billion, down 26.82% from the prior year.
  • Cash from Investing Activities came in at -$1.1 billion for Q2 2026 at Johnson & Johnson, down from -$1.0 billion in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $3.3 billion in Q2 2023 to a low of -$18.3 billion in Q2 2025.
  • Average Cash from Investing Activities over 5 years is -$3.5 billion, with a median of -$1.3 billion recorded in 2023.
  • Year-over-year, Cash from Investing Activities tumbled 1864.32% in 2022 and soared 191.22% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then fell by 9.82% to -$1.3 billion in 2024, then tumbled by 239.77% to -$4.5 billion in 2025, then soared by 75.25% to -$1.1 billion in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were -$1.1 billion in Q2 2026, -$1.0 billion in Q1 2026, and -$4.5 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -1.11 Bn
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn -1.20 Bn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -5.60 Bn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -3.11 Bn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 2.11 Bn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -1.61 Bn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn -424.26 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -1.66 Bn
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -49.35 Mn
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -51.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 -1.11 Bn
Mar 29, 2026 -1.04 Bn
Dec 28, 2025 -4.49 Bn
Sep 28, 2025 -542.00 Mn
Jun 29, 2025 -18.26 Bn
Mar 30, 2025 -297.00 Mn
Dec 29, 2024 -1.32 Bn
Sep 29, 2024 -3.13 Bn
Jun 30, 2024 -13.69 Bn
Mar 31, 2024 -464.00 Mn
Dec 31, 2023 -1.20 Bn
Oct 1, 2023 2.54 Bn
Jul 2, 2023 -3.78 Bn
Apr 2, 2023 3.32 Bn
Jan 1, 2023 -9.05 Bn
Apr 3, 2022 -3.63 Bn
Oct 3, 2021 -2.72 Bn
Jul 4, 2021 -419.00 Mn
Apr 4, 2021 -185.00 Mn
Jan 3, 2021 -7.90 Bn